CN104045642B - 含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药物的应用 - Google Patents
含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药物的应用 Download PDFInfo
- Publication number
- CN104045642B CN104045642B CN201310081148.8A CN201310081148A CN104045642B CN 104045642 B CN104045642 B CN 104045642B CN 201310081148 A CN201310081148 A CN 201310081148A CN 104045642 B CN104045642 B CN 104045642B
- Authority
- CN
- China
- Prior art keywords
- fluorophenyl
- base
- oxo
- phenyl
- indole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *N(*)C(CC(N(*)I=C)=O)=O Chemical compound *N(*)C(CC(N(*)I=C)=O)=O 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (5)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310081148.8A CN104045642B (zh) | 2013-03-14 | 2013-03-14 | 含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药物的应用 |
PCT/CN2014/073422 WO2014139458A1 (zh) | 2013-03-14 | 2014-03-14 | 含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310081148.8A CN104045642B (zh) | 2013-03-14 | 2013-03-14 | 含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104045642A CN104045642A (zh) | 2014-09-17 |
CN104045642B true CN104045642B (zh) | 2016-08-24 |
Family
ID=51499084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310081148.8A Expired - Fee Related CN104045642B (zh) | 2013-03-14 | 2013-03-14 | 含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药物的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104045642B (zh) |
WO (1) | WO2014139458A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108929324A (zh) * | 2017-05-22 | 2018-12-04 | 南开大学 | 新型1,1-环丙基二酰胺衍生物的制备与应用 |
CN109134480A (zh) * | 2018-10-19 | 2019-01-04 | 辽宁大学 | 一种新型4-苯氨基苯并呋喃并[2,3-d]嘧啶类化合物及其应用 |
MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
LT4084778T (lt) | 2019-12-30 | 2024-01-25 | Deciphera Pharmaceuticals, Llc | Amorfinės kinazės inhibitoriaus vaistinės formos ir jų panaudojimo būdai |
IL293864A (en) | 2019-12-30 | 2022-08-01 | Deciphera Pharmaceuticals Llc | Preparations of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3- phenylurea |
CN114957136A (zh) * | 2021-02-24 | 2022-08-30 | 南京科默生物医药有限公司 | 一种用作vegfr抑制剂的抗肿瘤化合物及其用途 |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037825A2 (en) * | 2003-10-14 | 2005-04-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein kinase inhibitors |
US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
CN101965351A (zh) * | 2007-12-21 | 2011-02-02 | 埃克塞里艾克西斯公司 | 苯并呋喃并嘧啶酮 |
-
2013
- 2013-03-14 CN CN201310081148.8A patent/CN104045642B/zh not_active Expired - Fee Related
-
2014
- 2014-03-14 WO PCT/CN2014/073422 patent/WO2014139458A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037825A2 (en) * | 2003-10-14 | 2005-04-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein kinase inhibitors |
US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
CN101965351A (zh) * | 2007-12-21 | 2011-02-02 | 埃克塞里艾克西斯公司 | 苯并呋喃并嘧啶酮 |
Non-Patent Citations (1)
Title |
---|
New 4-amino-7,8-dimethoxy-5H-pyrimido[5,4-b]indole derivatives: synthesis and studies as inhibitors of phosphodiesterases;Antonio Monge,等;《Archiv der Pharmazie (Weinheim, Germany)》;19931231;第326卷(第11期);第879-885页,尤其参见第880页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104045642A (zh) | 2014-09-17 |
WO2014139458A1 (zh) | 2014-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104045642B (zh) | 含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药物的应用 | |
CN109328059B (zh) | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 | |
CN102405217B (zh) | 氮杂薁化合物 | |
CN102149713B (zh) | 吡啶并吡啶酮衍生物及其制备方法和治疗用途 | |
CN106536503B (zh) | 一种酪氨酸激酶抑制剂及其用途 | |
TWI751163B (zh) | Fgfr4抑制劑、其製備方法和應用 | |
CN104011052B (zh) | 化合物 | |
CN107438607A (zh) | 作为fgfr抑制剂的双环杂环 | |
JP6321821B2 (ja) | 2,3,4,6−4置換ベンゼン−1,5−ジアミン誘導体、その製造方法および医薬品における使用 | |
JP6151919B2 (ja) | ヘタリールアミノナフチリジン | |
CN108329311B (zh) | 作为选择性雌激素受体下调剂的三环类化合物及其应用 | |
AU2015306561A1 (en) | Indazole compounds as FGFR kinase inhibitor, preparation and use thereof | |
JP6594571B2 (ja) | マルチキナーゼ阻害剤化合物、並びにその結晶形及びその使用 | |
CN104926788B (zh) | 取代哌啶类衍生物、含其的药物组合物及其在抗肿瘤中的应用 | |
CN111788207B (zh) | 二噁烷并喹啉类化合物及其制备方法与应用 | |
CN104736533B (zh) | Vegfr3抑制剂 | |
JP2013511501A (ja) | ピリジノピリジノン誘導体、その調製および治療用途 | |
JP2021536436A (ja) | キノリン誘導体から調製される新規な阻害剤 | |
CN103214481B (zh) | 新型咪唑并[1,2-a]吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 | |
WO2020001351A1 (zh) | Egfr抑制剂及其制备和应用 | |
CN107286140A (zh) | 取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用 | |
CN112047941B (zh) | 一种化合物及其制备由Flt3/c-Met激酶高表达所引起疾病的药物的应用 | |
CN104974132A (zh) | 多取代的吡啶化合物、制备方法、用途及药物组合物 | |
CN103509024B (zh) | 嘧啶并苯并氮杂卓类化合物及其作为抗肿瘤药物的应用 | |
JP2017532299A (ja) | Ftl3およびjakの阻害剤としての大環状n−アリール−2−アミノ−4−アリール−ピリミジンポリエーテルの誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY Free format text: FORMER OWNER: CISEN PHARMACEUTICAL CO., LTD. Effective date: 20150513 Free format text: FORMER OWNER: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY Effective date: 20150513 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150513 Address after: 200040 Beijing West Road, Shanghai, No. 1320, No. Applicant after: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY Address before: 272073 Shandong high tech Zone in Jining City, Tongji Science and Technology Industrial Park Applicant before: CISEN PHARMACEUTICAL Co.,Ltd. Applicant before: Shanghai Institute of pharmaceutical industry |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 |
|
CF01 | Termination of patent right due to non-payment of annual fee |